These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 18220056)
21. Doctors warn against using Avastin for macular degeneration. Kmietowicz Z BMJ; 2010 May; 340():c2483. PubMed ID: 20453011 [No Abstract] [Full Text] [Related]
22. Should Avastin be used to treat age-related macular degeneration in the NHS?--Yes. Raftery J; Dent L Eye (Lond); 2009 Jun; 23(6):1247-9. PubMed ID: 19407834 [No Abstract] [Full Text] [Related]
23. Position paper: the need for head-to-head studies comparing Avastin versus Lucentis. Schmucker C; Antes G; Lelgemann M Surv Ophthalmol; 2009; 54(6):705-7. PubMed ID: 19818262 [No Abstract] [Full Text] [Related]
24. Nice or not so nice. McColgan K J Perioper Pract; 2010 Nov; 20(11):386. PubMed ID: 21162353 [No Abstract] [Full Text] [Related]
25. Experience of New Brunswick ophthalmologists using intravitreal anti-vascular endothelial growth factor. Giberson M; Taylor V Can J Ophthalmol; 2015 Oct; 50(5):393-4. PubMed ID: 26455977 [No Abstract] [Full Text] [Related]
26. Why have UK doctors been deterred from prescribing Avastin? Cohen D BMJ; 2015 Apr; 350():h1654. PubMed ID: 25834024 [No Abstract] [Full Text] [Related]
27. GMC is criticised for refusing to disclose reasons behind its advice to support prescribing for Lucentis rather than Avastin for wet AMD. Cohen D BMJ; 2015 Apr; 350():h1981. PubMed ID: 25869865 [No Abstract] [Full Text] [Related]
28. A licence to cure. Aronson JK; Ferner RE BMJ; 2015 Apr; 350():h1723. PubMed ID: 25834026 [No Abstract] [Full Text] [Related]
29. New treatments for age-related macular degeneration. Imrie FR; Bailey C Age Ageing; 2007 Jan; 36(1):8-10. PubMed ID: 17264135 [No Abstract] [Full Text] [Related]
30. I've heard that new medications to treat wet age-related macular degeneration (AMD) are available. Are these new medications better than current treatments? Johns Hopkins Med Lett Health After 50; 2006 Dec; 18(10):8. PubMed ID: 17290531 [No Abstract] [Full Text] [Related]
31. The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration. Steinbrook R N Engl J Med; 2006 Oct; 355(14):1409-12. PubMed ID: 17021315 [No Abstract] [Full Text] [Related]
32. Identifying and eliminating the roadblocks to comparative-effectiveness research. Martin DF; Maguire MG; Fine SL N Engl J Med; 2010 Jul; 363(2):105-7. PubMed ID: 20519677 [No Abstract] [Full Text] [Related]
33. Good news about new macular degeneration drugs. Harv Health Lett; 2011 Jan; 36(3):7. PubMed ID: 21341413 [No Abstract] [Full Text] [Related]
35. The growing importance of pharmacoeconomics: the case of age-related macular degeneration. Smith AF Br J Ophthalmol; 2010 Sep; 94(9):1116-7. PubMed ID: 20576774 [No Abstract] [Full Text] [Related]
37. Survey of Victorian ophthalmologists who use ranibizumab to treat age-related macular degeneration: to identify current practice and modifiable risk factors relevant to post-injection endophthalmitis. Buck DA; Dawkins R; Kawasaki R; Sandhu SS; Allen PJ Clin Exp Ophthalmol; 2015 Apr; 43(3):277-9. PubMed ID: 25112536 [No Abstract] [Full Text] [Related]